Potential Predictors of Response to CGRP Monoclonal Antibodies in Chronic Migraine: Real-World Data.

IF 3.2 2区医学 Q2 CLINICAL NEUROLOGY

Current Pain and Headache Reports Pub Date : 2024-12-01 Epub Date: 2023-10-24 DOI:10.1007/s11916-023-01183-6

Carmen Sánchez-Rodríguez, Ana Beatriz Gago-Veiga, David García-Azorín, Ángel Luis Guerrero-Peral, Alicia Gonzalez-Martinez

{"title":"Potential Predictors of Response to CGRP Monoclonal Antibodies in Chronic Migraine: Real-World Data.","authors":"Carmen Sánchez-Rodríguez, Ana Beatriz Gago-Veiga, David García-Azorín, Ángel Luis Guerrero-Peral, Alicia Gonzalez-Martinez","doi":"10.1007/s11916-023-01183-6","DOIUrl":null,"url":null,"abstract":"Purpose of review: Real-world data (RWD) has identified potential predictors of response to anti-CGRP therapies in patients with chronic migraine (CM). This review aims to synthesize the most remarkable findings published to date regarding this topic.Recent findings: Migraine features such as unilateral pain and positive triptan response and chronic features such as daily headache or medication overuse (MO) emerge as predictors of positive outcomes, potentially linked to elevated baseline serum anti-calcitonin gene-related peptide (anti-CGRP) levels. Demographic and baseline characteristics, encompassing obesity, psychiatric comorbidities, and prior refractoriness to prophylactic treatments, are associated with poor responses in both treatment-naïve patients and after-switch scenarios. Nevertheless, the consistency of these predictors across diverse populations requires further investigation. Recent RWD literature highlights emerging predictors of response of different sources among patients with CM receiving anti-CGRP therapies. Comprehending these predictors and identifying novel biomarkers of response hold the potential to refine treatment strategies for CM patients, enhancing their management and therapeutic outcomes.","PeriodicalId":50602,"journal":{"name":"Current Pain and Headache Reports","volume":" ","pages":"1265-1272"},"PeriodicalIF":3.2000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pain and Headache Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11916-023-01183-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Real-world data (RWD) has identified potential predictors of response to anti-CGRP therapies in patients with chronic migraine (CM). This review aims to synthesize the most remarkable findings published to date regarding this topic.

Recent findings: Migraine features such as unilateral pain and positive triptan response and chronic features such as daily headache or medication overuse (MO) emerge as predictors of positive outcomes, potentially linked to elevated baseline serum anti-calcitonin gene-related peptide (anti-CGRP) levels. Demographic and baseline characteristics, encompassing obesity, psychiatric comorbidities, and prior refractoriness to prophylactic treatments, are associated with poor responses in both treatment-naïve patients and after-switch scenarios. Nevertheless, the consistency of these predictors across diverse populations requires further investigation. Recent RWD literature highlights emerging predictors of response of different sources among patients with CM receiving anti-CGRP therapies. Comprehending these predictors and identifying novel biomarkers of response hold the potential to refine treatment strategies for CM patients, enhancing their management and therapeutic outcomes.

查看原文本刊更多论文

慢性偏头痛CGRP单克隆抗体反应的潜在预测因子：真实世界数据。

综述目的：真实世界数据（RWD）已经确定了慢性偏头痛（CM）患者对抗CGRP治疗反应的潜在预测因素。这篇综述旨在综合迄今为止发表的关于这一主题的最显著的发现。最近的发现：偏头痛特征，如单侧疼痛和曲坦阳性反应，以及慢性特征，如每日头痛或药物过度使用（MO），成为阳性结果的预测因素，可能与基线血清抗降钙素基因相关肽（抗CGRP）水平升高有关。人口统计学和基线特征，包括肥胖、精神病合并症和既往预防性治疗的难治性，与治疗幼稚患者和转换后情况下的不良反应有关。然而，这些预测因素在不同人群中的一致性需要进一步调查。最近的RWD文献强调了接受抗CGRP治疗的CM患者不同来源反应的新预测因素。理解这些预测因素并确定新的反应生物标志物有可能完善CM患者的治疗策略，提高他们的管理和治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Pain and Headache Reports CLINICAL NEUROLOGY-

CiteScore

6.10

自引率

2.70%

发文量

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings regarding the diagnosis, treatment, and management of pain and headache. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care and prevention of pain and headache. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as anesthetic techniques in pain management, cluster headache, neuropathic pain, and migraine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.